RNS Number : 5059G

Avacta Group PLC

28 April 2025

Avacta Group plc

("Avacta" or "the Group" or "the Company")

Block Listing Six Monthly Return

LONDON AND PHILADELPHIA  - April 28, 2025, Avacta Therapeutics (AIM: AVCT, 'the Company'), a life sciences company developing next generation peptide drug conjugates (PDC) targeting powerful anti-tumor payloads directly to the tumor, today makes the following notification pursuant to Schedule Six of the AIM Rules for Companies regarding its existing block admission arrangements:

Name of applicant:		Avacta Group plc
Name of scheme:		EMI scheme
Period of return:	From:	28 October 2024		27 April 2025
Balance of unallotted securities under scheme(s) from previous return:		275,380
Plus:    The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):		nil
Less:    Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):		47,000
Equals:    Balance under scheme(s) not yet issued/allotted at end of period:		228,380

Name of applicant:			Avacta Group plc
Name of scheme:			LTIP/ESOS scheme
Period of return:	From:		28 October 2024		27 April 2025
Balance of unallotted securities under scheme(s):			5,913,257
Plus:    The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):			nil
Less:    Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):			4,366,882
Equals:    Balance under scheme(s) not yet issued/allotted at end of period:			1,546,375
Name of contact:		Brian Hahn, Company Secretary
Telephone number of contact:		+ 44 (0) 1904 217070

Ends-

For further information from Avacta Group plc, please contact:

Avacta Group plc Michael Vinegrad, Group Communications Director	https://avacta.com/
Peel Hunt (Nomad and Joint Broker) James Steel / Chris Golden	www.peelhunt.com
Panmure Liberum (Joint Broker) Emma Earl / Will Goode / Mark Rogers ICR Healthcare Mary-Jane Elliott / Jessica Hodgson / Stephanie Cuthbert	www.panmureliberum.com avacta@icrhealthcare.com
Investor Contact Renee Leck THRUST Strategic Communications	renee@thrustsc.com
Media Contact Carly Scaduto Carly Scaduto Consulting	Carly@carlyscadutoconsulting.com

About Avacta -  https://avacta.com/

Avacta Therapeutics is a clinical-stage life sciences company expanding the reach of highly potent cancer therapies with the pre|CISION^® platform. pre|CISION^® is a proprietary warhead delivery system based on a tumor-specific protease (fibroblast activation protein or FAP) that is designed to concentrate highly potent warheads in the tumor microenvironment while sparing normal tissues. Our innovative pipeline consists of pre|CISION^® peptide drug conjugates (PDC) or Affimer^® drug conjugates (AffDC) that leverage the tumor-specific release mechanism, providing unique benefits over traditional antibody drug conjugates.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

BLRPPUGACUPAGQR